Frequently Asked Questions about LEAP Award
How do I apply to the LEAP program?
You can apply by simply filling out a short application form (20 minutes) on our website. You can also click on the "APPLY NOW" button at the end of this page after you review all the FAQs.
Are we going to share your information with 3rd parties?
No, all your information will remain strictly confidential and will only be used for selection purposes.
Is there a geographic preference for applicants?
No, we believe that science has no boundary - we therefore invite academic researchers from all countries to participate in our LEAP program.
I have more than 5 molecules that I want to examine, can I submit more?
Only up to 5 molecules will be accepted for each application.
Can I submit more than one application?
Yes, you can submit more than one application, provided that each application has a distinct research question.
Is there any opportunity to publish novel findings generated through the LEAP program?
Absolutely! We have a proven record of helping academic researchers publish articles in peer-reviewed journals (see examples here). We value close collaboration with our academic partners and encourage sharing scientific findings with the academic community.
What are the requirements for a suitable query molecule?
The small molecules should have a molecular weight between 200 to 800 Dalton.
The active form of your small molecule must be submitted.
Metabolites may also be submitted if in the appropriate molecular weight range.
How are the finalists selected?
Selection will be based on the soundness of your research question and the impact of your projects. The query molecules have to have a viable synthetic path or preferably have been already synthesized so that scientists are able to perform subsequent bioassays.
If analysis in Ligand Express produces any novel findings, who owns the IP?
Any IP around the compound is retained by the PI/Institution and not by Cyclica.
What if I or my Institution decide to commercialize the compound after it’s analysis in Ligand Express, by spinning out a company or out-licensing the compound with a partner to continue its development?
The LEAP program has been created to allow PIs to explore polypharmacology of small molecules that are strictly for research purposes and expectation that results will be shared with the scientific community. If a PI/Institution decides to pursue a commercial interest in the compound after analysis in Ligand Express the parties (PI/Institution and Cyclica) agree to negotiate in good faith to establish a partnering agreement whereby Cyclica would receive suitable remuneration around milestones reached in developing the compound.